Palonosetron versus older 5-HT3 receptor antagonists for nausea prevention in patients receiving chemotherapy: A multistudy analysis

Journal of Community and Supportive Oncology

Volumn 12, Issue 7, 2014, Pages 250-258

  Morrow, Gary R ^a   Schwartzberg, Lee ^b   Barbour, Sally Y ^c   Ballinari, Gianluca ^d   Torn, Michael D ^e   Cox, David ^f  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b West Clinic   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d HELSINN HEALTHCARE SA   (Switzerland)

^e Statistical Resources   (United States)

^f EISAI INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; DEXAMETHASONE; DOLASETRON MESILATE; GRANISETRON; METOCLOPRAMIDE; ONDANSETRON; PALONOSETRON; PROCHLORPERAZINE; SEROTONIN 3 ANTAGONIST;

ADULT; ANXIETY DISORDER; ARTICLE; ASTHENIA; BLOOD CHEMISTRY; CANCER CHEMOTHERAPY; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAPHY; FATIGUE; FEMALE; HEADACHE; HEMATOLOGY; HUMAN; HYPERTRANSAMINASEMIA; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY (TOPIC); NAUSEA; NEOPLASM; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); URINALYSIS;

EID: 84991705972     PISSN: 23307749     EISSN: None     Source Type: Journal    
DOI: 10.12788/jcso.0058     Document Type: Article

References (32)

1. NCCN clinical practice guidelines in oncology (NCCN Guidelines): Antiemesis. v1.2013. National Comprehensive Cancer Network; 2012.
2. Roscoe JA, Morrow GR, Colagiuri B, et al. Insight in the prediction of chemotherapy-induced nausea. Support Care Cancer. 2010;18:869-876.
3. Grunberg SM, Warr D, Gralla RJ, et al. Evaluation of new antiemetic agents and defnition of antineoplastic agent emetogenicitystate of the art. Support Care Cancer. 2011;19(suppl 1)43S-47S.
4. Gralla RJ, Osoba D, Kris MG, et al. Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol. 1999;17:2971-2994.
5. Grunberg SM, Deuson RR, Mavros P, et al. Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer. 2004;100:2261-2268.
6. Hickok JT, Roscoe JA, Morrow GR, et al. 5-Hydroxytryptaminereceptor antagonists versus prochlorperazine for control of delayed nausea caused by doxorubicin: a URCC CCOP randomised controlled trial. Lancet Oncol. 2005;6:765-772.
7. Hesketh PJ. Chemotherapy-induced nausea and vomiting. N Engl J Med. 2008;358:2482-2494.
8. Endo T, Minami M, Hirafuji M, et al. Neurochemistry and neuropharmacology of emesis-the role of serotonin. Toxicology. 2000;153:189-201.
9. Hesketh PJ. Comparative review of 5-HT3 receptor antagonists in the treatment of acute chemotherapy-induced nausea and vomiting. Cancer Invest. 2000;18:163-173.
10. Hickok JT, Roscoe JA, Morrow GR, King DK, Atkins JN, Fitch TR. Nausea and emesis remain signifcant problems of chemotherapy despite prophylaxis with 5-hydroxytryptamine-3 antiemetics: a University of Rochester James P. Wilmot Cancer Center Community Clinical Oncology Program Study of 360 cancer patients treated in the community. Cancer. 2003;97:2880-2886.
11. Rojas C, Stathis M, Tomas AG, et al. Palonosetron exhibits unique molecular interactions with the 5-HT3 receptor. Anesth Analg. 2008;107:469-478.
12. Grunberg SM, Koeller JM. Palonosetron: a unique 5-HT3-receptor antagonist for the prevention of chemotherapy-induced emesis. Expert Opin Pharmacother. 2003;4:2297-2303.
13. Stoltz R, Cyong JC, Shah A, Parisi S. Pharmacokinetic and safety evaluation of palonosetron, a 5-hydroxytryptamine-3 receptor antagonist, in U.S. and Japanese healthy subjects. J Clin Pharmacol. 2004;44:520-531.
14. Stathis M, Pietra C, Rojas C, Slusher BS. Inhibition of substance P-mediated responses in NG108-15 cells by netupitant and palonosetron exhibit synergistic efects. Eur J Pharmacol. 2012;689:25-30.
15. Rojas C, Li Y, Zhang J, et al. Te antiemetic 5-HT3 receptor antagonist Palonosetron inhibits substance P-mediated responses in vitro and in vivo. J Pharmacol Exp Ter. 2010;335:362-368.
16. Morganroth J, Parisi S, Moresino C, Torn M, Cullen MT. High dose palonosetron does not alter ECG parameters including QTc interval in healthy subjects: results of a dose-response, double blind, randomized, parallel El4 study of palonosetron vs. moxifoxacin or placebo [abstract]. Eur J Cancer. 2007:5(suppl);158S-159S.
17. Yavas C, Dogan U, Yavas G, Araz M, Ata OY. Acute efect of palonosetron on electrocardiographic parameters in cancer patients: a prospective study. Supportive Care in Cancer. 2012;20:2343-2347.
18. Gonullu G, Demircan S, Demirag MK, Erdem D, Yucel I. Electrocardiographic fndings of palonosetron in cancer patients. Supportive Care in Cancer. 2012;20:1435-1439.
19. Charbit B, Alvarez JC, Dasque E, Abe E, Demolis JL, Funck-Brentano C. Droperidol and ondansetron-induced QT interval prolongation: a clinical drug interaction study. Anesthesiology. 2008;109:206-212.
20. Botrel TE, Clark OA, Clark L, Paladini L, Faleiros E, Pegoretti B. Efcacy of palonosetron (PAL) compared to other serotonin inhibitors (5-HT3R) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic (MoHE) treatment: systematic review and meta-Analysis. Support Care Cancer. 2011;19:823-832.
21. Sato Y, Hayakawa Y, Tatematsu M, Muro K, Noma H, Okamoto H. Antiemetic efect of palonosetron in advanced colorectal cancer patients receiving mFOLFOX6 and FOLFIRI: a retrospective survey. Gan To Kagaku Ryoho. 2012;39:1215-1219.
22. Gralla R, Lichinitser M, Van der Vegt S, et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol. 2003;14:1570-1577.
23. Eisenberg P, Figueroa-Vadillo J, Zamora R, et al. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Cancer. 2003;98:2473-2482.
24. Aapro M, Grunberg S, Manikhas G, et al. A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol. 2006;17:1441-1449.
25. Saito M, Aogi K, Sekine I, et al. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, doubledummy, randomised, comparative phase III trial. Lancet Oncol. 2009;10:115-124.
26. Schwartzberg L, Barbour SY, Morrow GR, Ballinari G, Torn MD, Cox D. Pooled analysis of phase III clinical studies of palonosetron versus ondansetron, dolasetron, and granisetron in the prevention of chemotherapy-induced nausea and vomiting (CINV). Support Care Cancer. 2014;22:469-477.
27. Rojas C, Tomas AG, Alt J, et al. Palonosetron triggers 5-HT(3) receptor internalization and causes prolonged inhibition of receptor function. Eur J Pharmacol. 2010;626:193-199.
28. Hesketh PJ, Van Belle S, Aapro M, et al. Diferential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specifc receptor antagonists. Eur J Cancer. 2003;39:1074-1080.
29. Rojas C, Slusher BS. Pharmacological mechanisms of 5-HT3 and tachykinin NK1 receptor antagonism to prevent chemotherapyinduced nausea and vomiting. Eur J Pharmacol. 2012;684:1-7.
30. Zofran (ondansetron hydrochloride) tablets; Zofran ODT (ondansetron) orally disintegrating tablets; Zofran (ondansetron hydrochloride) oral solution [prescribing information]. Research Triangle Park, NC, GlaxoSmithKline; 2013.
31. Roila F, Herrstedt J, Aapro M, et al. Guideline update for MASCC and ESMO in the prevention of chemotherapy-And radiotherapyinduced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol. 2010;21(suppl 5)(232V-243V.
32. Basch E, Prestrud AA, Hesketh PJ, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2011;29:4189-4198.